View Item 

Show simple item record

Ribavirin and cellular ribavirin‐triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus
dc.contributor.authorMueller, Scott W.
dc.contributor.authorKiser, Tyree H.
dc.contributor.authorMorrisette, Taylor
dc.contributor.authorZamora, Martin R.
dc.contributor.authorLyu, Dennis M.
dc.contributor.authorKiser, Jennifer J.
dc.date.accessioned2021-03-02T21:48:22Z
dc.date.available2022-03-02 16:48:21en
dc.date.available2021-03-02T21:48:22Z
dc.date.issued2021-02
dc.identifier.citationMueller, Scott W.; Kiser, Tyree H.; Morrisette, Taylor; Zamora, Martin R.; Lyu, Dennis M.; Kiser, Jennifer J. (2021). "Ribavirin and cellular ribavirin‐triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus." Transplant Infectious Disease 23(1): n/a-n/a.
dc.identifier.issn1398-2273
dc.identifier.issn1399-3062
dc.identifier.urihttps://hdl.handle.net/2027.42/166443
dc.description.abstractRespiratory syncytial virus (RSV) is responsible for significant morbidity and mortality in the lung transplant population. Oral and aerosolized ribavirin may improve outcomes in lung transplant patients with RSV; however, data relating ribavirin concentrations in plasma and intracellular ribavirin triphosphate (iRTP) concentrations in blood and bronchoalveolar lavage (BAL) fluid cells with efficacy and safety are lacking. We describe ribavirin and iRTP concentrations within various compartments in two adult lung transplant recipients with RSV who were sampled throughout successful treatment courses with oral and inhaled ribavirin. In patient 1, iRTP BAL concentrations decreased by 45% over 3 days after changing inhaled ribavirin to oral (6.32 to 3.43 pmol/106 cells). In patient 2, iRTP BAL concentrations were 103 pmol/106 cells after 5 days of oral followed by 5 days of inhaled ribavirin. Further study is needed to describe ribavirin pharmacokinetics in the respiratory compartment to inform clinical use of ribavirin for respiratory viruses.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherribavirin triphosphate
dc.subject.otherconcentration
dc.subject.otherlung transplant
dc.subject.otherrespiratory syncytial virus
dc.subject.otherribavirin
dc.titleRibavirin and cellular ribavirin‐triphosphate concentrations in blood and bronchoalveolar lavage fluid in two lung transplant patients with respiratory syncytial virus
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166443/1/tid13464_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166443/2/tid13464.pdf
dc.identifier.doi10.1111/tid.13464
dc.identifier.sourceTransplant Infectious Disease
dc.identifier.citedreferenceBurrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost‐efficiency. J Heart Lung Transplant. 2015; 34: 958 ‐ 962.
dc.identifier.citedreferenceMiller JP, Kigwana LJ, Streeter DG, Robins RK, Simon RK, Roboz J. The relationship between the metabolism of ribavirin and its proposed mechanism of action. Ann N Y Acad Sci. 1977; 284: 211 ‐ 229.
dc.identifier.citedreferenceSidwell RW, Robins RK, Hillyard IW. Ribavirin: an antiviral agent. Pharmacol Ther. 1979; 6: 123 ‐ 146.
dc.identifier.citedreferenceWu LS, Rower JE, Burton JR, et al. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015; 59: 2179 ‐ 2188.
dc.identifier.citedreferenceRower JE, Meissner EG, Jimmerson LC, et al. Serum and cellular ribavirin pharmacokinetic and concentration‐effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015; 70: 2322 ‐ 2329.
dc.identifier.citedreferenceJimmerson LC, Urban TJ, Truesdale A, et al. Variant inosine triphosphatase phenotypes are associated with increased ribavirin triphosphate levels. J Clin Pharmacol. 2017; 57: 118 ‐ 124.
dc.identifier.citedreferenceWu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D’Argenio DZ. Modeling ribavirin‐induced anemia in patients with chronic hepatitis C virus. CPT Pharmacometrics Syst Pharmacol. 2016; 5: 65 ‐ 73.
dc.identifier.citedreferenceHynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012; 46: 558 ‐ 566.
dc.identifier.citedreferenceNam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019; 366: l5021.
dc.identifier.citedreferenceWeinberg A, Lyu DM, Li S, Marquesen J, Zamora MR. Incidence and morbidity of human metapneumovirus and other community‐acquired respiratory viruses in lung transplant recipients. Transpl Infect Dis. 2010; 12: 330 ‐ 335.
dc.identifier.citedreferenceMcCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003; 22: 745 ‐ 753.
dc.identifier.citedreferencePelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009; 28: 67 ‐ 71.
dc.identifier.citedreferenceLiu V, Dhillon GS, Weill D. A multi‐drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart‐lung transplant recipients. Transpl Infect Dis. 2010; 12: 38 ‐ 44.
dc.identifier.citedreferenceJimmerson LC, Ray ML, Bushman LR, et al. Measurement of intracellular ribavirin mono‐, di‐ and triphosphate using solid phase extraction and LC‐MS/MS quantification. J Chromatogr B Analyt Technol Biomed Life Sci. 2015; 978–979: 163 ‐ 172.
dc.identifier.citedreferenceSimiele M, D’Avolio A, Baietto L, et al. Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. Antimicrob Agents Chemother. 2011; 55: 2976 ‐ 2978.
dc.identifier.citedreferenceChapman EH, Kurec AS, Davey FR. Cell volumes of normal and malignant mononuclear cells. J Clin Pathol. 1981; 34: 1083 ‐ 1090.
dc.identifier.citedreferenceSegel GB, Cokelet GR, Lichtman MA. The measurement of lymphocyte volume: importance of reference particle deformability and counting solution tonicity. Blood. 1981; 57: 894 ‐ 899.
dc.identifier.citedreferenceGao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA. 1993; 90: 8925 ‐ 8928.
dc.identifier.citedreferenceFuchs EJ, Kiser JJ, Hendrix CW, et al. Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus‐infected patients. J Antimicrob Chemother. 2016; 71: 1597 ‐ 1600.
dc.identifier.citedreferenceStockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006; 3: e343.
dc.identifier.citedreferenceBooth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short‐term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289: 2801 ‐ 2809.
dc.identifier.citedreferenceMomattin H, Mohammed K, Zumla A, Memish ZA, Al‐Tawfiq JA. Therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) – possible lessons from a systematic review of SARS‐CoV therapy. Int J Infect Dis. 2013; 17: e792 ‐ e798.
dc.identifier.citedreferenceHruska JF, Bernstein JM, Douglas RG, Hall CB. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother. 1980; 17: 770 ‐ 775.
dc.identifier.citedreferenceKawana F, Shigeta S, Hosoya M, Suzuki H, De Clercq E. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother. 1987; 31: 1225 ‐ 1230.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
tid13464_am.pdf
Size:
388.7KB
Format:
PDF
View/Open
Name:
tid13464.pdf
Size:
334.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.